高级检索

    茚达特罗与噻托溴铵治疗慢性阻塞性肺疾病的疗效比较

    Effects of indacaterol and tiotropium bromide on chronic obstructive pulmonary disease

    • 摘要: 目的 对比茚达特罗和噻托溴铵对稳定期中重度慢性阻塞性肺疾病(COPD)患者的速效及长效支气管扩张作用。方法 将125例COPD患者分为茚达特罗150μ9组(n=42)、茚达特罗300μg组(n=41)和噻托溴铵组(n=42)。观察各组给药前30 min,给药后5 min、30 min、1 h、4 h1s钟用力呼气容积(FEV1),治疗4周后FEV1谷值、6分钟步行试验(6MWT)及COPD评估测试(CAT)评分。结果 茚达特罗150μg组和300μg组在给药5 min、30 min FEV1均较噻托溴铵组明显升高(P<0.05),给药30 min茚达特罗300μg组FEV1升高程度较150μg组更为显著(P<0.05)。给药1 h、4h 3组FEVI较基线均有升高,茚达特罗300μg组FEV1升高较茚达特罗150μg组及噻托溴铵组更显著(P<0.05),茚达特罗150μg组与噻托溴铵组FEV1升高水平差异无统计学意义(P>0.05)。给药持续4周可见茚达特罗300μg组较茚达特罗150μg组、噻托溴铵组FEV1谷值改善更明显(P<0.05),茚达特罗150μg与噻托溴铵疗效差异无统计学意义(P>0.05)。3组持续治疗4周后CAT评分均较治疗前显著下降(P<0.05)。茚达特罗150μg组CAT评分下降程度与噻托溴铵组差异无统计学意义(P>0.05)。茚达特罗300μg组CAT评分下降程度较茚达特罗150μg组与噻托溴铵组更为显著(P<0.05)。治疗4周后3组6MWT明显提高(P<0.05),茚达特罗150μg组与噻托溴铵组6MWT改善水平差异无统计学意义(P<0.05),茚达特罗300μg组6MWT改善水平较茚达特罗150μg组及噻托溴铵组更为显著(P<0.05)。结论 低剂量茚达特罗(150μg)长效扩张支气管作用与噻托溴铵水平相当,高剂量茚达特罗(300μg)长效扩张支气管作用优于低剂量茚达特罗及噻托溴铵。高剂量茚达特罗在改善患者呼吸困难水平及提高患者运动能力方面优于低剂量茚达特罗及噻托溴铵。

       

      Abstract: Objective To compare the rapid and long-term bronchiectasis effects of indacaterol and tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease(COPD).Methods A total of 125 patients with COPD were divided into three groups:indacaterol 150 μg group(n=42),indacaterol 300 μg( n=41)and tiotropium bromide group(n=42).The following parameters were observed:forced expiratory volume in 1 second(FEV1)30 min before administration and 5 min,30 min,1 h,4 h after administration,the valley value of FEV1,6-minute walking test(6 MWT)and COPD assessment test(CAT)scores after 4 weeks of treatment. Results FEV1 in the indacaterol 150 μggroup and 300 μg group was significantly higher than that in the tiotropium bromide group(P<0.05)at 5 min and 30 min after administration,and the FEV1 in the indacaterol 300μg group was significantly higher than that in the 150μg group at 30 min after administration(P<0.05).The FEV1 levels in the three groups at 1 h and4 h after administration were higher than those in the baseline.The FEV1 level in the indacaterol 300 μg group was higher than that in the indacaterol 150 μg group and the tiotropium bromide group(P<0.05).There was no significant difference in the FEV1 level between the indacaterol 150 μ group and the tiotropium bromide group(P>0.05).After4 weeks of treatment,the valley value of FEV1 in the indacaterol 300 μg group was better than that in the indacaterol 150μg group and the tiotropium bromide group(P<0.05).There was no significant difference between the indacaterol 150μg group and the tiotropium bromide group(P>0.05).After 4 weeks of continuous treatment,the CAT scores of the three groups were significantly lower than those before treatment(P<0.05).There was no significant difference in the decrease of CAT score between the 150 μg indacaterol group and the tiotropium bromide group(P>0.05).The decrease of CAT score in the indacaterol 300 μg group was more significant than that in the indacaterol 150 μg group and the tiotropium bromide group(P<0.05).After 4 weeks of treatment,6 MWT in the three groups increased significantly(P<0.05).There was no significant difference in the improvement of 6 MWT between the 150 μg indacaterol group and the tiotropium bromide group(P<0.05).The improvement of 6 MWT in the indacaterol 300 μg group was more significant than that in the indacaterol 150 μg group and the tiotropium bromide group(P<0.05).Conclusions The longterm bronchiectasis effect of low-dose indacaterol(150 μg)is similar to that of tiotropium bromide.The long-term bronchiectasis effect of high-dose indacaterol(300 μg)is better than that of low-dose indacaterol and tiotropium bromide.High-dose indacaterol is superior to low-dose indacaterol and tiotropium bromide in improving dyspnea and motor ability.

       

    /

    返回文章
    返回